Table 2 Univariable and multivariable analysis of overall survival.

From: The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

 

Univariable

Multivariable

hazard ratio

95% CI

p

hazard ratio

95% CI

p

Age

  

0.003

  

0.141

 < 65

1

  

1

  

 ≥ 65

1.34

1.10–1.63

 

1.23

0.93–1.64

 

Sarcomatoid Feature

  

0.018

  

0.003

 No

1

  

1

  

 Yes

1.41

1.06–1.89

 

1.72

1.21–2.46

 

Nephrectomy

  

 < 0.001

  

0.018

 No

1.94

1.58–2.39

 

1.53

1.08–2.22

 

 Yes

1

  

1

  

Systemic Treatment

  

0.034

  

0.704

 Sunitinib

1

  

1

  

 Pazopanib

1.22

1.01–1.48

 

1.05

0.79–1.39

 

Anemia

  

 < 0.001

  

0.014

 No

1

  

1

  

 Yes

1.93

1.59–2.35

 

1.41

1.07–1.86

 

Hypercalcemia

  

 < 0.001

  

0.894

 No

1

  

1

  

 Yes

2.21

1.52–3.21

 

1.04

0.53–2.06

 

LDH Elevation

  

 < 0.001

  

0.190

 No

1

  

1

  

 Yes

1.97

1.47–2.64

 

1.32

0.87–2.00

 

ECOG Performance Score

  

 < 0.001

  

 < 0.001

 ECOG 0–1

1

  

1

  

 ECOG 2–3-4

3.18

2.58–3.91

 

2.75

2.04–3.71

 

Time to Systemic Treatment

  

 < 0.001

  

0.411

 < 1 year

1.59

1.30–1.96

 

1.14

0.82–1.59

 

 ≥ 1 year

1

  

1

  

Previous Cytokine Use

  

0.491

   

 No

1

     

 Yes

1.06

0.88–1.28

    

Bone or CNS Metastasis

  

 < 0.001

  

0.141

 No

1

  

1

  

 Yes

1.60

1.28–2.00

 

1.23

0.93–1.64

 

Number of Systemic Treatment*

  

0.061

  

0.289

 1

1.19

0.99–1.44

 

1.16

0.88–1.52

 

 > 1

1

   

1

 

SII

  

 < 0.001

  

0.018

 Low

1

  

1

  

 High

1.70

1.40–2.08

 

1.41

1.06–1.87

 
  1. CI confidence interval, CNS central nervous system, ECOG eastern cooperative oncology group, LDH lactate dehydrogenase, SII systemic immune-inflammation index.
  2. Significant values are in bold.
  3. *Except for interferon.
Back to article page